115 related articles for article (PubMed ID: 38294206)
1. Design, synthesis, and biological evaluation of naphthoylamide derivatives as inhibitors of STAT3 phosphorylation.
Lu J; Yan X; Lai W; Jiang LH; Shen LQ; Wu AQ; Zhao C
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300526. PubMed ID: 38294206
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
[TBL] [Abstract][Full Text] [Related]
3. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
4. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
5. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
6. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
[TBL] [Abstract][Full Text] [Related]
7. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
Liu Z; Wang H; Guan L; Lai C; Yu W; Lai M
Br J Pharmacol; 2020 Jan; 177(2):298-313. PubMed ID: 31499589
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of benzo[b]thiophene 1,1-dioxide derivatives as potent STAT3 inhibitors.
Li WZ; Xi HZ; Wang YJ; Ma HB; Cheng ZQ; Yang Y; Wu ML; Liu TM; Yang W; Wang Q; Liao MY; Xia Y; Zhang YW
Chem Biol Drug Des; 2021 Nov; 98(5):835-849. PubMed ID: 34416096
[TBL] [Abstract][Full Text] [Related]
9. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol.
Wei N; Li J; Fang C; Chang J; Xirou V; Syrigos NK; Marks BJ; Chu E; Schmitz JC
Oncogene; 2019 Mar; 38(10):1676-1687. PubMed ID: 30348989
[TBL] [Abstract][Full Text] [Related]
10. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3).
Brambilla L; Genini D; Laurini E; Merulla J; Perez L; Fermeglia M; Carbone GM; Pricl S; Catapano CV
Mol Oncol; 2015 Jun; 9(6):1194-206. PubMed ID: 25777967
[TBL] [Abstract][Full Text] [Related]
11. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.
Li S; Zhang W; Yang Y; Ma T; Guo J; Wang S; Yu W; Kong L
Eur J Med Chem; 2016 Nov; 124():1006-1018. PubMed ID: 27783972
[TBL] [Abstract][Full Text] [Related]
12. 4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway.
Ji P; Yuan C; Ma S; Fan J; Fu W; Qiao C
Bioorg Med Chem; 2016 Dec; 24(23):6174-6182. PubMed ID: 27816267
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study.
Wang F; Feng KR; Zhao JY; Zhang JW; Shi XW; Zhou J; Gao D; Lin GQ; Tian P
Bioorg Med Chem; 2020 Dec; 28(24):115822. PubMed ID: 33126089
[TBL] [Abstract][Full Text] [Related]
14. Chemical probes that competitively and selectively inhibit Stat3 activation.
Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors.
Zhang C; Yang L; Yang X; Gao Q; Qu Y; Wu L
Bioorg Chem; 2023 Jul; 136():106541. PubMed ID: 37062104
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition.
Xu S; Fan R; Wang L; He W; Ge H; Chen H; Xu W; Zhang J; Xu W; Feng Y; Fan Z
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):236-251. PubMed ID: 34894961
[TBL] [Abstract][Full Text] [Related]
17. Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer.
Huang M; Chen Z; Zhang L; Huang Z; Chen Y; Xu J; Zhang J; Shu X
Bioorg Med Chem Lett; 2016 Nov; 26(21):5172-5176. PubMed ID: 27727126
[TBL] [Abstract][Full Text] [Related]
18. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
19. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
